1
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Condition(s):Multiple SclerosisLast Updated:April 4, 2023Not yet recruiting
Cladribine: 161 Clinical Trials, Page 1 of 17
Hide Studies Not Open or Pending
2
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Condition(s):Multiple Sclerosis, Secondary Progressive; Multiple SclerosisLast Updated:July 28, 2023Recruiting
3
Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia
Condition(s):Acute Myeloid LeukemiaLast Updated:April 29, 2022Recruiting
4
Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
Condition(s):Multiple Sclerosis, Relapsing-RemittingLast Updated:June 15, 2023Active, not recruiting
5
Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
Condition(s):Multiple SclerosisLast Updated:August 9, 2023Active, not recruiting
6
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
Condition(s):Multiple SclerosisLast Updated:September 15, 2023Active, not recruiting
7
Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes
Condition(s):Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, AcuteLast Updated:June 28, 2018Unknown status
8
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets
Condition(s):Multiple SclerosisLast Updated:January 13, 2022Recruiting
9
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Condition(s):Leukemia; Myelodysplastic Syndromes; Acute Myeloid LeukemiaLast Updated:September 13, 2023Not yet recruiting
10
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis
Condition(s):Multiple Sclerosis; Multiple Sclerosis, Relapsing-RemittingLast Updated:July 11, 2023Active, not recruiting